

This article was downloaded by:

On: 27 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

Acycloadenosine Derivatives as Inhibitors of 5'-Deoxy-5'-Methylthioadenosine Phosphorylase (MesADo PASE)

Shih-Hsi Chu^a; Zhi-Hao Chen^a; Todd M. Savarese^a; Charles E. Nakamura^a; Robert E. Parks Jr.^a; Elie Abushamb^b

^a Bran University, Providence, RI ^b University of Rhode Island, Kingston, RI

To cite this Article Chu, Shih-Hsi , Chen, Zhi-Hao , Savarese, Todd M. , Nakamura, Charles E. , Parks Jr., Robert E. and Abushamb, Elie(1989) 'Acycloadenosine Derivatives as Inhibitors of 5'-Deoxy-5'-Methylthioadenosine Phosphorylase (MesADo PASE)', *Nucleosides, Nucleotides and Nucleic Acids*, 8: 5, 829 — 832

To link to this Article: DOI: 10.1080/07328318908054223

URL: <http://dx.doi.org/10.1080/07328318908054223>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

**ACYCLOADENOSINE DERIVATIVES AS INHIBITORS OF 5'-DEOXY-5'-METHYL-
THIOADENOSINE PHOSPHORYLASE (MeSAdo PASE)**

Shih-Hsi Chu, Zhi-Hao Chen, Todd M. Savarese, Charles E. Nakamura,
Robert E. Parks, Jr.* and Elie Abushanab†

Brown University, Providence, RI 02912

†University of Rhode Island, Kingston, RI 02881

Abstract: Four classes of acyclo analogs of 5'-methylthioadenosine were synthesized and tested as inhibitors of mammalian methylthioadenosine phosphorylase. Halogenated dihydroxypropyl acycloadenosines were most potent, i.e. $K_i = 0.2 - 0.7 \mu\text{M}$.

MeSAdo Pase is required to salvage the methionine and adenine components of MeSAdo generated during polyamine synthesis. Experimental tumors, e.g. L-1210 murine leukemia, that lack this enzyme are highly sensitive to the cytotoxicity of inhibitors of purine de novo biosynthesis, e.g. 6-methylthioinosine, folate antagonists; therefore, as proposed earlier¹ potent inhibitors of MeSAdo Pase might cause enzyme-containing cells to be more sensitive to inhibitors of purine de novo biosynthesis, e.g. glutamine antagonists, folate antagonists, etc. Initial tests of this concept with the MeSAdo Pase inhibitor, 5'-chloroformycin, increased the sensitivity of the L-5178Y leukemia (enzyme-containing) to methotrexate². The present study explored various analogs of MeSAdo related to acyclovir and DHPG as inhibitors of MeSAdo Pase.


BIOLOGICAL ACTIVITY. Although acycloadenosine (1) itself was inactive ($K_i > 170 \mu\text{M}$), its 2-deoxy-2-halogenated congener's (2), (3) and (4), inhibited Sarcoma 180 MeSAdo Pase with K_i values in the range of 4 to 9 μM . The 2-deoxy analog of acycloadenosine, 9-(ethoxymethyl)adenine, was a weak inhibitor ($K_i = 74 \mu\text{M}$). The analogs of 9-(1,3-dihydroxy-2-propoxymethyl)adenine (DHPA), which possess the equivalent of the C(3')-OH of methylthioribose, were more potent inhibitors of MeSAdo Pase than their acycloadenosine-like congeners. While the parent compound, DHPA,

was inactive ($K_i > 100 \mu\text{M}$), replacement of a hydroxyl group by a halogen (Cl, Br, I) (5), (7) and (8) gave K_i values in the range of 0.7 to 0.2 μM . 5'-Methylthio- and 5'-halogenated derivatives of 2'-deoxy-1',2'-seco-adenosine (11-14) had low activity. At low phosphate concentration (3.5 mM) the 9-(phosphonoalkyl)adenines (16) act as multisubstrate inhibitors of the enzyme. Compounds with longer (pentyl, hexyl, heptyl) acyclic tails bind more tightly (K_i values in the range of 70 to 15 μM) than those with shorter tails, i.e. propyl, butyl (K_i values $>250 \mu\text{M}$). At high (50 mM) potassium phosphate concentrations, the inhibitions were ablated, indicating interactions with the phosphate binding site of the enzyme.


These acyclic adenosines represent new classes of MeSAdo Pase inhibitors. In terms of SAR, the finding that many of these acyclic adenosine analogs bind as well or better than the natural substrate, MeSAdo ($K_m = 2 \mu\text{M}$), suggests that a flexible acyclic tail permits better orientation for enzyme binding than a relatively rigid pentose. The nearly 10 fold lower K_i values of the halogenated DHPA analogs as compared to the acycloadenosine analogs stress the importance of the C(3') hydroxyl group. Results with 9-(phosphonoalkyl)adenines suggest the design of potent multisubstrate inhibitors of MeSAdo Pase based on an acyclic adenosine structure.

SYNTHESIS OF HALOGENATED ACYCLOADENOSINES


9-[(2-Chloroethoxy)methyl]adenine (2) and 9-[(2-bromoethoxy)methyl]adenine (3) were synthesized by treating acycloadenine (1) in HMPA with SOCl_2 and SOBr_2 , respectively. (2) 92% yield. m.p. 215°C (dec). UV(EtOH): λ_{max} 259 nm (14,000); (3) 81% yield m.p. 205°C ; UV(EtOH): λ_{max} 259 nm (14,200); 9-[(2-iodoethoxy)methyl]adenine (4) was iodinated smoothly by methyltriphenoxyphosphonium iodide in dry THF at -70°C . (4) 74% yield, m.p. 188°C ; UV(EtOH): λ_{max} 259 nm (14,600).




9-[(1-Chloromethyl-2-hydroxyethoxy)methyl]adenine (5) was synthesized by reacting adenine bis-trimethylsilyl ester with 1-chloro-3-benzoyloxy-2-propoxymethyl chloride and deblocking with 0.1 N aqueous NaOH. m.p. 215°C ; UV(EtOH): λ_{max} 259 nm (14,800).



9-[(1-Bromomethyl-2-hydroxyethoxy)methyl]adenine (**7**) and 9-[(1-Iodomethyl-2-hydroxyethoxy)methyl]adenine (**8**) were synthesized by halogenation of (**6**) by the method of Ogilvie *et al.*⁶ using lithium bromide or sodium iodide respectively. (**7**) Yield 35% m.p. 194°C. UV(EtOH): λ_{\max} 259 nm (14,700); (**8**) Yield 39% m.p. 200°C dec.; UV(EtOH): λ_{\max} 259 nm (14,350).




5'-SUBSTITUTED 1',2' SECO-2'-DEOXYADENINE NUCLEOSIDES



The chloromethyl ethers prepared from (2R,3S) and (2S,3S) - 1,3-di-O-benzylbutane 1,2,3-triol⁴ (**9**) were treated with the sodium salt of 6-chloropurine in acetonitrile⁵ to give the 6-chloropurine analogs (**10**) as a mixture of N-7 and N-9 isomers. Chromatographic separation followed by heating with ammonia and subsequent debenzoylation over Pd/C furnished the adenosine analogs (**11**). The 5'-bromo (**12**) and 5'-chloro (**13**) substituents were added by treatment of (**10**) with triphenylphosphine and carbon tetrabromide or carbon tetrachloride respectively. This reaction was not totally selective necessitating the chromatographic separation of the 5'-halo from the 3',5'-dihalo derivatives. The 5'-methylthio compounds (**14**) were obtained by direct displacement of the 5'-bromides with potassium methyl mercaptide.

9-(PHOSPHONOALKYL)ADENINES. A series of 9-(phosphonoalkyl)adenines with carbon chains ranging from 3-7 C atoms was prepared from the respective 6-chloropurine analogs⁶ by heating with ammonia.

Scheme V



Acknowledgments: This work was supported by USPHS grants CA 07340, CA 13943 and CA 20892.

REFERENCES

1. R.E. Parks, Jr., T.M. Savarese and S.-H. Chu. pp 141-156, 1982. *New Approaches to the Design of Antineoplastic Agents*. Ed. T.T. Bardos and T.I. Kalman, Elsevier Science Publishing Co., Inc. NY.
2. E. Chu, T.M. Savarese, S.-H. Chu, M.-Y. Chu, M.C. Wiemann, P. Calabresi and R.E. Parks, Jr., *Am. Fed. Clin. Res.* (1984).
3. K.K. Ogilvie, N. Nguyen-ba, M.F. Gillen, B.K. Radatus, U.O. Cheriyan, H.R. Hanna, K.O. Smith and K.S. Galloway, *Can. J. Chem.* 62, 241 (1984).
4. E. Abushanab, P. Vemishetti, R.W. Leiby, H.K. Singh, A.B. Mikkilineni, D.C.J. Wu, R. Saibaba, and R.P. Panzica, *J. Org. Chem.* 53, 2598 (1988).
5. Z. Kazimierczuk, H.B. Cottam, G.R. Ravenkar and R.K. Robins, *J. Am. Chem. Soc.* 106, 6379 (1984).
6. C.E. Nakamura, S.-H. Chu, J.D. Stoeckler and R.E. Parks, Jr., *Biochem. Pharm.* 35, 133 (1986).